Novo Nordisk moves to strengthen obesity effortsAfter securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space Share XNovo Nordisk moves to strengthen obesity effortshttps://pharmaphorum.com/news/novo-nordisk-moves-to-strengthen-obesity-efforts/
Novo Nordisk nears EU approval of obesity drug WegovyDanish drugmaker Novo Nordisk is hoping to launch its once-weekly injectable treatment for obesity, Wegovy, in the EU Share XNovo Nordisk nears EU approval of obesity drug Wegovyhttps://pharmaphorum.com/news/novo-nordisk-nears-eu-approval-of-obesity-drug-wegovy/
Regeneron, AZ team up on drugs for obesity “superpower” geneAstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at Share XRegeneron, AZ team up on drugs for obesity “superpower” genehttps://pharmaphorum.com/news/regeneron-az-team-up-on-drugs-for-obesity-superpower-gene/
FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s WegovyNovo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which Share XFDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovyhttps://pharmaphorum.com/news/fda-ends-obesity-drug-drought/
Novo Nordisk’s semaglutide effective against obesity in new trialNovo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new, Share XNovo Nordisk’s semaglutide effective against obesity in new trialhttps://pharmaphorum.com/news/novo-nordisks-semaglutide-effective-obesity-new-trial/
Price cut leads NICE to back Novo Nordisk’s obesity drug SaxendaNovo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in Share XPrice cut leads NICE to back Novo Nordisk’s obesity drug Saxendahttps://pharmaphorum.com/news/price-cut-leads-nice-to-back-novo-nordisks-obesity-drug-saxenda/
Merck & Co to repurpose failed obesity drug for NASHMerck & Co is to pay $10 million to Hanmi to repurpose an obesity drug discarded by Johnson Share XMerck & Co to repurpose failed obesity drug for NASHhttps://pharmaphorum.com/news/merck-co-to-repurpose-failed-obesity-drug-for-nash/
Could GLP-1 drugs treat space headaches? NASA wants to know.Experts from NASA are keeping a close eye on UK research that tests whether drugs commonly used in Share XCould GLP-1 drugs treat space headaches? NASA wants to know.https://pharmaphorum.com/news/nasa-looks-on-as-uk-researchers-test-glp-1-drugs-against-space-headaches/
Rhythm doesn’t miss a beat as obesity drug clears phase 3 testRhythm Pharma says it has reported positive results for its obesity drug setmelanotide in two phase 3 trials, Share XRhythm doesn’t miss a beat as obesity drug clears phase 3 testhttps://pharmaphorum.com/news/rhythm-doesnt-miss-a-beat-as-obesity-drug-clears-phase-3-test/
